BIOMAT Database Logo BIOMAT Database Logo

Hypotensive and natriuretic effects of nifedipine in essential hypertension. Role of renal kallikrein-kinin-prostaglandin and renin-angiotensin-aldosterone systems. 1986

K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga

To assess the role of renal kallikrein-kinin-prostaglandin and renin-angiotensin-aldosterone systems in the diuretic and natriuretic actions of nifedipine, a calcium-channel blocker, 20 mg of nifedipine was administered orally to 15 patients with essential hypertension. Nifedipine promptly induced a hypotensive effect and an increase in pulse rate. Urine volume, urinary sodium excretion, and creatinine clearance were significantly increased after the administration of nifedipine by 63.5%, 48.5% and 12.4%, respectively. Urinary excretion of kallikrein and prostaglandin E were also significantly increased after the administration of nifedipine by 29.4% and 50.0%, respectively. The change in urinary kallikrein excretion was significantly correlated with that in urine volume (r = 0.70, p less than 0.01) or that in urinary sodium excretion (r = 0.86, p less than 0.01). In addition, the change in urinary prostaglandin E excretion was also significantly correlated with that in urine volume (r = 0.72, p less than 0.01) or that in urinary sodium excretion (r = 0.53, p less than 0.05). Plasma aldosterone concentration did not change despite of the marked increase in plasma renin activity, and plasma aldosterone concentration/plasma renin activity ratio decreased after the administration of nifedipine. These results suggest that the augmented renal kallikrein-kinin-prostaglandin system and the suppressed secretion of aldosterone may be associated with the diuretic and natiuretic action of nifedipine and may contribute to the reduction in blood pressure that is caused mainly by its vasodilatory action.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females

Related Publications

K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
Renal kallikrein-kinin system and prostaglandin in hypertension: their relation to renin-angiotensin-aldosterone system.
January 1979, Advances in experimental medicine and biology,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
[Arterial hypertension. Physiopathologic approach by means of the renin-angiotensin-aldosterone and kallikrein-kinin-prostaglandin systems].
January 1983, Revista clinica espanola,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
Regulatory effects of salt diet on renal renin-angiotensin-aldosterone, and kallikrein-kinin systems.
December 2002, International immunopharmacology,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
January 1981, Acta medica Scandinavica. Supplementum,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
Relation of renin-angiotensin system to kallikrein-kinin and prostaglandin systems in hypertension.
January 1983, Acta medica Scandinavica. Supplementum,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
[Studies on kallikrein-kinin system in essential hypertension: urinary kallikrein-kinin system and renin-angiotensin-aldosterone system (author's transl)].
May 1978, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
The pathophysiological role of renal dopamine, kallikrein kinin and prostaglandin systems in essential hypertension.
January 1987, Agents and actions. Supplements,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
[Effects of captopril on renin-angiotensin-aldosterone system and kallikrein-kinin system in patients with essential hypertension].
November 1984, Nihon Jinzo Gakkai shi,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
[Studies on renal prostaglandin E in essential hypertension: relationships among urinary prostaglandin E, sodium balance, renin-angiotensin-aldosterone system and renal kallikrein-kinin system (author's transl)].
December 1978, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
K Tsunoda, and K Abe, and K Omata, and K Kudo, and M Sato, and M Kohzuki, and M Tanno, and M Seino, and M Yasujima, and K Yoshinaga
[The role of the kallikrein-kinin and renin-angiotensin-aldosterone systems in the development of hypertension in glomerulonephritis].
December 1990, Klinicheskaia meditsina,
Copied contents to your clipboard!